贲门癌和癌旁肠上皮化生组织CD10、CK7、CK20和CDX2的表达变化
|
摘要
研究背景
河南林州地区是食管鳞癌(Esophageal squamous cell carcinoma，SCC)高发区同时也是贲门癌(Gastric cardia adenocarcinoma，GCA)高发区。近二十年来，西方国家食管贲门交界部腺癌的发病率明显上升，并认为反流性食管炎-Barrett's食管(肠上皮化生)-不典型增生-食管或食管贲门交界部腺癌是该部位主要发病模式。但是，与西方国家明显不同的是，中国食管癌高发区95％以上为食管鳞癌，食管腺癌的发生率，反流性食管炎，特别是Barrett's食管的发生率均较低，所观察到的贲门癌也主要位于齿状线下方。贲门癌旁肠上皮化生(Intestinal metaplasia，IM)的特征及其与GCA的关系尚不清楚。本课题组以往的研究发现IM可能是GCA的癌前病变，但西方国家的学者认为贲门部的IM不具有癌变风险。这些研究提示河南GCA高发区IM及GCA可能具有独特的发生机制和分子变化特点。文献报道CK7、CK20和CD10能够区分胃食管交界部IM和腺癌的来源，来自食管的IM和腺癌分别特异表达“Barrett's CK7/CK20模式”和“CK7+／20-模式”，而来源于贲门的组织不具有这种特点。CDX2是一种肠道上皮特异性基因，在早期的胃IM组织甚至尚未出现杯状细胞时就已有表达。本研
Background
Linzhou and nearby counties in Henan Province are the high incidence area for esophageal squamous cell carcinoma (SCC) and gastric cardia adenocarcinoma (GCA). In the last two decades, adenocarcinoma at gastro-esophageal junction (GEJ) has increased dramatically in western countries and the sequence from reflux esophagitis-Barrett's esophagus (intestinal metaplasia) -dysplasia-adenocarcinoma has been hypothesized as the histogenesis model for the adenocarcinoma originated at GEJ in western countries. Comparing with western country, distinctly difference is 95% esophageal cancer is SCC in Linzhou. The incidences of esophageal adenocarcinoma, reflux esophagitis and especially Barrett's esophagus are much lower in Chinese population. And most of GCA occurs below the Z-line in China. The prevalence of IM adjacent to GCA and its relation with GCA has not been well characterized. Our research group found that intestinal metaplasia (IM) might be a
河南林州地区是食管鳞癌(Esophageal squamous cell carcinoma，SCC)高发区同时也是贲门癌(Gastric cardia adenocarcinoma，GCA)高发区。近二十年来，西方国家食管贲门交界部腺癌的发病率明显上升，并认为反流性食管炎-Barrett's食管(肠上皮化生)-不典型增生-食管或食管贲门交界部腺癌是该部位主要发病模式。但是，与西方国家明显不同的是，中国食管癌高发区95％以上为食管鳞癌，食管腺癌的发生率，反流性食管炎，特别是Barrett's食管的发生率均较低，所观察到的贲门癌也主要位于齿状线下方。贲门癌旁肠上皮化生(Intestinal metaplasia，IM)的特征及其与GCA的关系尚不清楚。本课题组以往的研究发现IM可能是GCA的癌前病变，但西方国家的学者认为贲门部的IM不具有癌变风险。这些研究提示河南GCA高发区IM及GCA可能具有独特的发生机制和分子变化特点。文献报道CK7、CK20和CD10能够区分胃食管交界部IM和腺癌的来源，来自食管的IM和腺癌分别特异表达“Barrett's CK7/CK20模式”和“CK7+／20-模式”，而来源于贲门的组织不具有这种特点。CDX2是一种肠道上皮特异性基因，在早期的胃IM组织甚至尚未出现杯状细胞时就已有表达。本研
Background
Linzhou and nearby counties in Henan Province are the high incidence area for esophageal squamous cell carcinoma (SCC) and gastric cardia adenocarcinoma (GCA). In the last two decades, adenocarcinoma at gastro-esophageal junction (GEJ) has increased dramatically in western countries and the sequence from reflux esophagitis-Barrett's esophagus (intestinal metaplasia) -dysplasia-adenocarcinoma has been hypothesized as the histogenesis model for the adenocarcinoma originated at GEJ in western countries. Comparing with western country, distinctly difference is 95% esophageal cancer is SCC in Linzhou. The incidences of esophageal adenocarcinoma, reflux esophagitis and especially Barrett's esophagus are much lower in Chinese population. And most of GCA occurs below the Z-line in China. The prevalence of IM adjacent to GCA and its relation with GCA has not been well characterized. Our research group found that intestinal metaplasia (IM) might be a
引文
1. Yang GR, Qiu SL. Incidence rate of adenocarcinoma of the gastric cardia, and endoscopic classification of early cardia carcinoma in Henan Province, the People's Republic of China. Endoscopy, 1987; 19:7-10
2. Li JY, Ershow AG, Chen ZJ, et al. A case control studies of cancer of the esophageal and gastric cardia in Linxian. Int J Cancer, 1989; 43:755-781
3．王立东，高文俊，杨万才等。林州市人民医院9年间食管癌，贲门癌3933例分析。河南医科大学学报，1997；32：9-11
4. Victor T, Toit RD, Jordan AM, et al. No evidence for point mutation in codons 12, 13 and 61 of the ras gene in a high incidence area for esophageal and gastric cancer. Cancer Res, 1990; 50:4911-4913
5. Boring CC, Squires TS, Tong T. Cancer statistics. CA, 1991; 41:19-36
6. Powell J, McConky CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer, 1990; 62:440-443
7. De Groot KM. Cancer of the oesophagus—quo vadis? S Afr Med J, 2006; 96: 197-198
8. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA, 1993; 270:1320-1323
9. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagastric junction. Gastroenterology, 1993; 104: 510-513
10. Botterweck AM, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol, 2000; 29:645-654
11. Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutation in human tumors and cell lines: updated compilation and future prospects. Nucleic Acid Res, i997; 25:151-157
12. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of??the esophageal and gastric cardia. JAMA, 1991; 265:1287-1289
13．周琦，王立东。贲门癌的生物学特征。世界华人消化杂志，1998；6：636-637
14. Stephen S. Stemberg. Histology for pathologists. New York: Lippincott-Raven Publishers, 1997
15. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol, 1980; 33:801-810
16. Stollman N. The columnar-lined (Barrett's) esophagus. Postgraduate Medicine, 2000; 107:59-65
17. Chen XX, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. London: Oxford University Press, 1999
18. Ruol A, Parenti k, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer, 2000; 88:2520-2526
19. Sampliner RE, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol, 2002; 97:1888-1895
20. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology, 2003; 125:586-590
21．聂敏海。细胞角蛋白在口腔粘膜癌变过程中的变化。现代口腔医学杂志，2000； 14：55-57
22. Eichner R, Bonitz P, Sun TT. Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression. J Cell Biol, 1984; 98:1388-1396
23. Shen B, Ormsby AH, Shen C, et al. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer, 2002; 94:820-831
24. Sarbia M, Donner A, Franke C, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and??immunohistochemistry. Hum Pathol, 2004; 35:371-376
25. Ormsby AH, Goldblum JR, Rice TW, et al. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology, 2001; 38:307-311
26．宋艳，李凌。肠道上皮特异性基因CDX2。世界华人消化杂志，2004；12： 443-445
27. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol, 2003; 199:36-40
28．刘贵生，龚均，程鹏等。肠特异性转录因子CDX2在不同亚型肠化生及胃癌组织中的表达。癌症，2006；25：185-189
29．陈虹，王立东，范宗民等。贲门肠上皮化生三种组织化学染色方法的比较。河南医学研究，2003；12：10-13
30．王立东，刘宾，郭瑞锋等。食管癌高发区居民食管和贲门上皮癌变过程中 C-erbB2和c-myc表达的变化。郑州大学学报(医学版)，2002；37：739-742
31．沈铭昌，王恭，裘宋良等。胃肿瘤。全国胃癌防治研究协作组病理组编著。胃及十二指肠粘膜活检病理。沈阳：辽宁人民出版社，1981
32. Voutilainen M, Farkkila M, Juhola M, et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut, 1999; 45:644-648
33. EI-Zimaity HM, Ramchatesingh J, Saeed MA, et al. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol, 2001; 54:679-683
34. Wang LD, Zheng S, Zheng ZY, et al. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol, 2003; 9:1156-1164
35. Pera M. Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett's Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. World J Surg, 2003; 27:999-1008
36．杜兴贵，胡承江，唐慕湘等。胃黏膜肠上皮化生与胃癌关系的黏液组织化学??和免疫组织化学研究。同济医科大学陨阳医学院学报，1994；13：196-200
37．孙宇，金晓明，刘彦铖等。胃黏膜肠上皮化生类型与胃癌发生的关系。哈尔滨医科大学学报，2000；34：160-162
38．谢玉泉，李吉友，胡綝等。胃癌高发区肠上皮化生与异型增生的关系。北京医科大学报，1998；30：78-80
39. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the Gastroesophageal junction. Gastroenterology, 1999; 117:218-228
40. van Sandick JW, Van Lanschot JB, van Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction. Am J Clin Pathol, 2002; 117:117-125
41. Chen YY, Wang HH, Antonioli DA, et al. Significance of acid-mucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol, 1999; 30:1488-1495
42. Ormsby AH, Goldblum JG, Rice TW, et al. Cytoketatin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol, 1999; 30:288-294
43. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreacitivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000; 119:683-690
44. Mario Sarbia, Andreas Donner, Claus Franke, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Human Pathology, 2004; 35:371-376
45. Satoh K, Mutoh H, Eda A, et al. Alberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: effect of eradication of Helicobacter pylori. Helicobacter, 2002; 7:192-198
46. Shiroshita H, Watanabe H, Ajioka Y, et al. Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. Pathol Int, 2004; 54: 311-321
47. Powell J, McConkey CC, Gillison EW, et al. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer, 2002; 102:422-42748. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol, 1992; 23:475-476
49. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol, 2005; 92:151-159
50. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev, 1992; 1:265-269
51. Devesa SS, Blot WJ, Fraumeni JE. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer, 1998; 83: 2049-2053
52. Viste A, Soreide O, Glattre E. Stomach cancer: major trends in incidence during introduction of gastroscopy service in Normay. Scand J Gastroenterol, 1985; 20: 99-108
53. Levi F, La Vecchia C, Te VC. Descriptive epidemiology of adenocarcinoma of the cardia and distal stomach in the Swiss canton ofVaud. Tumori, 1990; 76:167-171
54. Locke GR, Talley NJ, Carpenter HA, et al. Changes in the site and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology, 1995; 109:1750-1756
55．常英，龚均，刘斌等。内镜检查中胃贲门部肠上皮化生的研究。西安交通大学学报(医学版)，2004：25：350-352
56．王立东，冯常炜，邹建湘等。食管癌高发区楼村居民贲门与胃窦上皮病变的比较。河南医科大学学报，1997；32：53-54
57. Gao SG. Wang LD, Fan ZM, et al. Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol, 2005; 11: 4634-46371．Barrett食管诊断和治疗—美国胃肠病学会芝加哥会议总结。胃肠病学，2005； 10：182-186
2．覃江。Barrett食管与食管腺癌的研究进展。医学综述，2001；7：14-15
3．吴诚，施宾，朱墚。Barrett's食管(BE)研究进展。胃肠病学与肝病学杂志 2005．14：215-217
4. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology, 2005; 129: 1825-1831.
5. Clark GWB, Ireland AP, Peters JH, et al. Short segments Barrett's esophagus: A prevalent complication of gastroesophageal reflux disease with malignant potential. J Gastrointest Surg, 1997; 1:113-222
6. Cameron A J, Zinsmeister AR, Ballard D J, et al. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology, 1990; 99:918-922
7. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology, 1992; 103:1241-1245
8. Drovdlic CM, Goddard KA, Chak A, et al. Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet, 2003; 40:651-656
9． 王立东，冯常炜，周琦等。食管癌高发区楼村居民食管病变普查结果分析。河南医科大学学报，1997；32：6-8
10．刘宾，王立东。关于Barrett食管。世界华人消化杂志，1999；7：921-925
11. Ter RB, Castell DO. Gastroesophageal reflux disease in patients with columar lined esophagus. Gsatroenterol Clin North Am, 1997; 26:549-563
12．许军英，张锦坤。Barrett食管的酸反流类型。中华消化杂志，1997；17： 265-267
13. Eisen GM, Sandler RS, Murray S, et al. The relationship between??gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastro Enterol, 1997; 92:27-31
14. Stein HJ, Cauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nisson fundaplication. J Gastrointest Surg, 1998; 2:333-341
15. Abe Y, Ohara S, Koike T, et al. The prevalence of Helicobacter pylori infection and mestatus of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol, 2004; 99:1213-1221
16. Carmona-Sanchez R, Navarro-cano G. Prevalence of helicobacter pylori infection in patients with reflux esophagitis. A case-control study. Rev Gastroenterol Mex, 2003; 68:23-28
17. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol, 1980; 33:801-810
18. Filipe MI, Potet F, Bogomoletz WV, et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut, 1985; 26:1319-1326
19. Ming SC, Goldman H. Pathology of the gastrointestinal tract. Baltimore: Williams & Wilkens Publishers, 1998, Second edition.
20．周涛，陈汉松，甘梅富。胃黏膜不同类型肠上皮化生的癌胚抗原观察。温州医学院学报，1994；3：161-162
21．刘贵生，龚均，张军等。Barrett食管、贲门部与胃窦部肠上皮化生的比较研究。中华消化内镜杂志，2005；22：223-226
22. Jauregui HO, Davessar K, Hale JH, et al. Mucin histochemistry of intestinal metaplasia in Barrett's esophagus. Mod Pathol, 1998; 1: 188-192
23. van Sandick JW, Van Lanschot JB, van Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction. Am J Clin Pathol, 2002; 117:117-125
24. Ormsby AH, Goldblum JG; Rice TW, et al. Cytoketatin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol, 1999; 30:288-294
25. Ormsby AH, Vaezi MF, Richter JE, et al. Cvtokeratin immunoreacitivity patterns??in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000; 119:683-690
26. Couvelard A, Cauvin J-M, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 2001; 49: 761-766
27. Gulmann C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus. Appl Immunohistochem Mol Morphol, 2004; 12: 142-147
28. Ei-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol, 2001; 96: 1378-1382
29. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol, 2002; 15: 611-616
30. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology, 1999; 35: 517-524
31. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer, 2000, 88: 856-861
32. Kim BW, Kim KM, Lee BI, et al. Expression of trefoil peptides in the subtypes of intestinal metaplasia. Peptides, 2004; 25: 779-783
33. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol, 2002; 97: 2514-2523
34. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 ML. Am J??Surg Pathol, 2001; 25: 87-94
35. Polkowski W, van Lanschot JJ, Kate FJ, et al. The value of p53 and Ki67 as markers for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol, 1995; 4: 163-171
36. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 2002; 122: 1800-1807
37. Tselepis C, Perry I, Dawson C, et al. Tumor necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene, 2002; 21: 6071-6081
38. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc, 2001; 76: 438-446
39. Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett's oesophagus. Gut, 2005; 54: i38-i42
40. Doak SH, Jenkins GJS, Parry EM, et al. Chromosome hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut, 2003; 52: 623-628
41. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut, 2005; 54;6-12
42. Pera M, Cameron AJ, Trastek VF et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology, 1993, 104: 510-513
43. Cameton AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology, 1995; 109: 1541-1546
44. Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis, 2003; 14: 128-135
45. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology, 1996; 110: 614-621
46. Ortiz Hidalgo C, De La Vega G, Aguirre Garcia J. The histopathology and biologic prognostic factors of Barrett's esophagus: a review. J Clin Gastroenterol,??1998; 26:324-333
47. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA, 2001; 285: 2331-2338
48. Lagergren J, Nandurkar S, Talley N, et al. Gastroesophageal reflux with symptom: a dangerous factor of esophageal adenocarcinoma. N Engl J Med, 1999; 340: 825-831
49. Sharma P. Recent advances in Barrett's esophagus: short segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis, 1999; 10: 93-102
50. Stephen S. Sternberg. Histology for pathologists. New York: Lippincott-Raven Publishers. Second Edition, 1997,461-493
51. Spechler SJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology, 2004; 126: 567-575
52. McClave SA, Boyce HW Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic criterion. Gastrointest Endosc, 1987; 33: 413-416
53. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol, 1998; 93: 1033-1036
54. Chandrasoma P. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg, 1997; 9: 270-278
55. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology, 1998; 114: 633-639
56. Spechler SJ. Are we underestimating acid reflux? Gut, 2004; 53: 162-163
57. Watanabe T, Tada M, Nagai H, et al. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology, 1998; 115: 642-648
58. Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Am Surg, 1997; 226: 522-53259. Manuel Pera. Trends in incidence and prevalence of Specialized Intestinal Metaplasia, Barrett's Esophagus, and Adenocarcinoma of the gastroesophageal Junction. World J Surg, 2003; 10:999-1008
60．常英，龚均，刘斌等。内镜检查中胃贲门部肠上皮化生的研究。西安交通大学学报(医学版)，2004；25：350-352
61．王立东，冯常炜，邹建湘等。食管癌高发区楼村居民贲门与胃窦上皮病变的比较。河南医科大学学报，1997；32：53-54
62．王俊宽，王立东，焦新英等。贲门癌癌旁肠上皮化生检测。郑州大学学报医学版，2006；41：14-16
63. Dresner SM, Griffin SM, Wayman J, et al. Human model of duodenogastro-oesophageal reflux in the development of Barrett's metaplasia. Br J Surg, 2003; 90:1120-1128
64. Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 2001; 49:761-766
65. Gao SG, Wang LD, Fan ZM, et al. Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol, 2005; 11: 4634-4637
66. Sarbia M, Donner A, Franke C, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Hum Pathol, 2004; 35:371-376
67. Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable? BMC Clin Pathol, 2003; 3:5-12
68．冯笑山，高社干，马保根等。贲门癌癌旁和无症状人群贲门黏膜活检肠上皮化生组织中p53和PCNA的表达。郑州大学学报医学版，2006；41：30-32
69. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric eardia. Gut, 2000; 46:9-1370. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology, 1999; 116: 277-285
71. Sampliner RE, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol, 2002; 97: 1888-1895
72. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology, 2003; 125: 586-590
73. Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut, 2001; 49:2-4
74. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut, 2003; 52: 1-4
75. Sakaki N, Kozawa H, Egawa N, et al. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther, 2002; 16: 198-203
76. Prabhu SR, Amrapurkar AD, Amrapurkar DN. Role of Helicobater pylori in gastric carcinoma. Natl Med India, 1995; 8: 58-60
77. Matsukura N, Onda M, Tokunaga A, et al. Mucosal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal metaplasia detected by the Tes-Tape method in resection specimens after gastrectomy for gastric cancer. Cancer, 1995; 75: 1472-1477
78. Kneller RW, You Weicheng, Chang Yunsheng, et al. Cigarette smoking and other risk factors for the progression of precancerous stomach lesions. J Natl Cancer Inst. 1992; 84: 1261-1266
79. Stemmermann GN, Nomura MY, Chyou PH, et al. Impact of diet and smoking on risk of developing intestinal metaplasia of the stomach. Dig Dis and Sci, 1990; 35: 433-438
80. Yanai H, Takada K, Shimizu N, et al. Epstein-Barrvirus infection in non-carcinoma gastric epithelium. J Pathol, 1997; 183: 293-29881．杨光霖。胃粘膜肠化生类型及其在胃粘膜活检中的意义。临床与实验病理学杂志，1991，7：327-330
82. Eidt S, Stolte M. Prevalence of intestinal metaplasia in Helicobacter pylori gastritis. Scand J Gastroenterol, 1994; 29:607-610
83．徐光炜，游伟程，昌云生等。胃癌预防的研究。中国肿瘤临床，1998；25： 782-785
84．谢玉泉，李吉友，胡綝等。胃癌高发区肠上皮化生与异型增生的关系。北京医科大学报，1998；30：78-80
85. Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. Word J Gastroenterol, 2005; 11: 7131-7135
86. You WC, Zhang L, Gail MH, et al. Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol, 1998; 27:945-948
87. Rubio CA, Jonasson J, Nesi G. et al. Extensive intestinal metaplasia in gastric carcinoma and in other lesions requiring surgery: a study of 3,421 gastrectomy specimens from dwellers of the Atlantic and Pacific basins. J Clin Pathol, 2005; 58:1271-1277
88. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the Gastroesophageal junction. Gastroenterology, 1999; 117:218-228
89. Fraser AG; Peng SL, Jass JR. Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. J Gastroenterol Hepatol, 1998; 13:560-565
90. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol, 2001; 54:679-683
91．沈金库，林静，张林西等。胃黏膜上皮肠化类型与胃癌相关性研究。胃肠病学与肝病学杂志，1998；7：384-386
92. Shiao YH, Rugge M, Correa P, et al. p53 alteration in gastric precancerous lesions. Am J Pathol, 1994; 144:511-517
93. Sung JJY, Leung WK, Go MYY, et al. Cyclooxygenase-2 expression in??Helicobacter pylori -associated pre-malignant and malignant gastric lesions. Am J Pathol, 2000; 157: 729-735
94. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell, 1995; 83: 493-501
95. Filipe MI, Osborn M, Linehan J, et al. Expression of transforming growth factorα, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer, 1995; 71: 30-36
96. Yu J, Leung WK, Ng EK, et al. Effect of H. pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther, 2001; 15: 1505-1512
97. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun, 2003; 300: 813-818
98. Bai YQ, Yamamoto H, Akiyama Y, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett, 2002; 176: 47-55
99. Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology, 2002; 123: 1565-1577
100. Mutoh H, Sakurai S, Satoh K, et al. CDX1 induced intestinal metaplasia in the transgenic mouse stomach: Comparative study with CDX2 transgenic mice. Gut, 2004; 53:1416-1423
101. Leung WK, Kim JJ, Kim JG, et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol, 2000; 156: 537-543
102. Leung SY, Yuen ST, Chung LP, et al. hMLHl promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequencymicrosatellite instability. Cancer Res, 1999; 59: 159-164
103. To KF, Leung WK, Lee TL, et al. Promoter hypermethylation of tumor-related ??genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer, 2002; 102:623-628
104. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res, 2001; 61:2847-2851
105. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med, 2005; 25:197-222
106. Lauwers GY. Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma. J Clin Gastroenterol, 2003; 36:S37-S43
107. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer, 1999; 83:615-619
108. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 2001; 345:784-789
109. Leung WK, Sung JJY. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmachol Ther, 2002; 16:1209-1216
110．谢辉，王莉，顾霞。不同粘液物质与胃癌关系的研究。新疆医科大学学报，2005； 28：443-445
111. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer, 1994; 57:324-329
1l2. Genta RM, Rugge M. Review article: pre-neoplastic states of the gastric mucosa——a practical approach for the perplexed clinician. Aliment Pharmacol Ther, 2001; 15:43-50
113. Cassaro M, Rugge M, Gutierrez O, et al. Topographic pattems of intestinal metaplasia and gastric cancer. Am J Gastroenterol, 2000; 95:1431-1438
114. Hansson LE, Nyren O, Hesting AW. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med, 1996, 335:242-249
115. Hattori T. Development of gastric carcinomas of the stomach. Cancer, 1986; 57: 1528-1534
116. Meining A, Morgner A, Miehlke S, et al. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Beat Practice & Reasearch. 2001: 15:983-998117.Ectors N, Dixon MF. The prognostic value sulohomucin positive intestinal metaplasia in development of gastric cancer. Histopathology, 1986; 10: 1271-1277
2. Li JY, Ershow AG, Chen ZJ, et al. A case control studies of cancer of the esophageal and gastric cardia in Linxian. Int J Cancer, 1989; 43:755-781
3．王立东，高文俊，杨万才等。林州市人民医院9年间食管癌，贲门癌3933例分析。河南医科大学学报，1997；32：9-11
4. Victor T, Toit RD, Jordan AM, et al. No evidence for point mutation in codons 12, 13 and 61 of the ras gene in a high incidence area for esophageal and gastric cancer. Cancer Res, 1990; 50:4911-4913
5. Boring CC, Squires TS, Tong T. Cancer statistics. CA, 1991; 41:19-36
6. Powell J, McConky CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer, 1990; 62:440-443
7. De Groot KM. Cancer of the oesophagus—quo vadis? S Afr Med J, 2006; 96: 197-198
8. Blot WJ, Devesa SS, Fraumeni JF. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA, 1993; 270:1320-1323
9. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagastric junction. Gastroenterology, 1993; 104: 510-513
10. Botterweck AM, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol, 2000; 29:645-654
11. Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutation in human tumors and cell lines: updated compilation and future prospects. Nucleic Acid Res, i997; 25:151-157
12. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of??the esophageal and gastric cardia. JAMA, 1991; 265:1287-1289
13．周琦，王立东。贲门癌的生物学特征。世界华人消化杂志，1998；6：636-637
14. Stephen S. Stemberg. Histology for pathologists. New York: Lippincott-Raven Publishers, 1997
15. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol, 1980; 33:801-810
16. Stollman N. The columnar-lined (Barrett's) esophagus. Postgraduate Medicine, 2000; 107:59-65
17. Chen XX, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. London: Oxford University Press, 1999
18. Ruol A, Parenti k, Zaninotto G, et al. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett esophagus and adenocarcinoma of the gastric cardia. Cancer, 2000; 88:2520-2526
19. Sampliner RE, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol, 2002; 97:1888-1895
20. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology, 2003; 125:586-590
21．聂敏海。细胞角蛋白在口腔粘膜癌变过程中的变化。现代口腔医学杂志，2000； 14：55-57
22. Eichner R, Bonitz P, Sun TT. Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression. J Cell Biol, 1984; 98:1388-1396
23. Shen B, Ormsby AH, Shen C, et al. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Cancer, 2002; 94:820-831
24. Sarbia M, Donner A, Franke C, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and??immunohistochemistry. Hum Pathol, 2004; 35:371-376
25. Ormsby AH, Goldblum JR, Rice TW, et al. The utility of cytokeratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology, 2001; 38:307-311
26．宋艳，李凌。肠道上皮特异性基因CDX2。世界华人消化杂志，2004；12： 443-445
27. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol, 2003; 199:36-40
28．刘贵生，龚均，程鹏等。肠特异性转录因子CDX2在不同亚型肠化生及胃癌组织中的表达。癌症，2006；25：185-189
29．陈虹，王立东，范宗民等。贲门肠上皮化生三种组织化学染色方法的比较。河南医学研究，2003；12：10-13
30．王立东，刘宾，郭瑞锋等。食管癌高发区居民食管和贲门上皮癌变过程中 C-erbB2和c-myc表达的变化。郑州大学学报(医学版)，2002；37：739-742
31．沈铭昌，王恭，裘宋良等。胃肿瘤。全国胃癌防治研究协作组病理组编著。胃及十二指肠粘膜活检病理。沈阳：辽宁人民出版社，1981
32. Voutilainen M, Farkkila M, Juhola M, et al. Complete and incomplete intestinal metaplasia at the oesophagogastric junction: prevalences and associations with endoscopic erosive oesophagitis and gastritis. Gut, 1999; 45:644-648
33. EI-Zimaity HM, Ramchatesingh J, Saeed MA, et al. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol, 2001; 54:679-683
34. Wang LD, Zheng S, Zheng ZY, et al. Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol, 2003; 9:1156-1164
35. Pera M. Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett's Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. World J Surg, 2003; 27:999-1008
36．杜兴贵，胡承江，唐慕湘等。胃黏膜肠上皮化生与胃癌关系的黏液组织化学??和免疫组织化学研究。同济医科大学陨阳医学院学报，1994；13：196-200
37．孙宇，金晓明，刘彦铖等。胃黏膜肠上皮化生类型与胃癌发生的关系。哈尔滨医科大学学报，2000；34：160-162
38．谢玉泉，李吉友，胡綝等。胃癌高发区肠上皮化生与异型增生的关系。北京医科大学报，1998；30：78-80
39. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the Gastroesophageal junction. Gastroenterology, 1999; 117:218-228
40. van Sandick JW, Van Lanschot JB, van Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction. Am J Clin Pathol, 2002; 117:117-125
41. Chen YY, Wang HH, Antonioli DA, et al. Significance of acid-mucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol, 1999; 30:1488-1495
42. Ormsby AH, Goldblum JG, Rice TW, et al. Cytoketatin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol, 1999; 30:288-294
43. Ormsby AH, Vaezi MF, Richter JE, et al. Cytokeratin immunoreacitivity patterns in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000; 119:683-690
44. Mario Sarbia, Andreas Donner, Claus Franke, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Human Pathology, 2004; 35:371-376
45. Satoh K, Mutoh H, Eda A, et al. Alberrant expression of CDX2 in the gastric mucosa with and without intestinal metaplasia: effect of eradication of Helicobacter pylori. Helicobacter, 2002; 7:192-198
46. Shiroshita H, Watanabe H, Ajioka Y, et al. Re-evaluation of mucin phenotypes of gastric minute well-differentiated-type adenocarcinomas using a series of HGM, MUC5AC, MUC6, M-GGMC, MUC2 and CD10 stains. Pathol Int, 2004; 54: 311-321
47. Powell J, McConkey CC, Gillison EW, et al. Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer, 2002; 102:422-42748. Haggitt RC. Adenocarcinoma in Barrett's esophagus: a new epidemic? Hum Pathol, 1992; 23:475-476
49. Pera M, Manterola C, Vidal O, et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol, 2005; 92:151-159
50. Powell J, McConkey CC. The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev, 1992; 1:265-269
51. Devesa SS, Blot WJ, Fraumeni JE. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer, 1998; 83: 2049-2053
52. Viste A, Soreide O, Glattre E. Stomach cancer: major trends in incidence during introduction of gastroscopy service in Normay. Scand J Gastroenterol, 1985; 20: 99-108
53. Levi F, La Vecchia C, Te VC. Descriptive epidemiology of adenocarcinoma of the cardia and distal stomach in the Swiss canton ofVaud. Tumori, 1990; 76:167-171
54. Locke GR, Talley NJ, Carpenter HA, et al. Changes in the site and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology, 1995; 109:1750-1756
55．常英，龚均，刘斌等。内镜检查中胃贲门部肠上皮化生的研究。西安交通大学学报(医学版)，2004：25：350-352
56．王立东，冯常炜，邹建湘等。食管癌高发区楼村居民贲门与胃窦上皮病变的比较。河南医科大学学报，1997；32：53-54
57. Gao SG. Wang LD, Fan ZM, et al. Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol, 2005; 11: 4634-46371．Barrett食管诊断和治疗—美国胃肠病学会芝加哥会议总结。胃肠病学，2005； 10：182-186
2．覃江。Barrett食管与食管腺癌的研究进展。医学综述，2001；7：14-15
3．吴诚，施宾，朱墚。Barrett's食管(BE)研究进展。胃肠病学与肝病学杂志 2005．14：215-217
4. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology, 2005; 129: 1825-1831.
5. Clark GWB, Ireland AP, Peters JH, et al. Short segments Barrett's esophagus: A prevalent complication of gastroesophageal reflux disease with malignant potential. J Gastrointest Surg, 1997; 1:113-222
6. Cameron A J, Zinsmeister AR, Ballard D J, et al. Prevalence of columnar-lined (Barrett's) esophagus: comparison of population-based clinical and autopsy findings. Gastroenterology, 1990; 99:918-922
7. Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology, 1992; 103:1241-1245
8. Drovdlic CM, Goddard KA, Chak A, et al. Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet, 2003; 40:651-656
9． 王立东，冯常炜，周琦等。食管癌高发区楼村居民食管病变普查结果分析。河南医科大学学报，1997；32：6-8
10．刘宾，王立东。关于Barrett食管。世界华人消化杂志，1999；7：921-925
11. Ter RB, Castell DO. Gastroesophageal reflux disease in patients with columar lined esophagus. Gsatroenterol Clin North Am, 1997; 26:549-563
12．许军英，张锦坤。Barrett食管的酸反流类型。中华消化杂志，1997；17： 265-267
13. Eisen GM, Sandler RS, Murray S, et al. The relationship between??gastroesophageal reflux disease and its complications with Barrett's esophagus. Am J Gastro Enterol, 1997; 92:27-31
14. Stein HJ, Cauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nisson fundaplication. J Gastrointest Surg, 1998; 2:333-341
15. Abe Y, Ohara S, Koike T, et al. The prevalence of Helicobacter pylori infection and mestatus of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol, 2004; 99:1213-1221
16. Carmona-Sanchez R, Navarro-cano G. Prevalence of helicobacter pylori infection in patients with reflux esophagitis. A case-control study. Rev Gastroenterol Mex, 2003; 68:23-28
17. Jass JR. Role of intestinal metaplasia in the histogenesis of gastric carcinoma. J Clin Pathol, 1980; 33:801-810
18. Filipe MI, Potet F, Bogomoletz WV, et al. Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres. Gut, 1985; 26:1319-1326
19. Ming SC, Goldman H. Pathology of the gastrointestinal tract. Baltimore: Williams & Wilkens Publishers, 1998, Second edition.
20．周涛，陈汉松，甘梅富。胃黏膜不同类型肠上皮化生的癌胚抗原观察。温州医学院学报，1994；3：161-162
21．刘贵生，龚均，张军等。Barrett食管、贲门部与胃窦部肠上皮化生的比较研究。中华消化内镜杂志，2005；22：223-226
22. Jauregui HO, Davessar K, Hale JH, et al. Mucin histochemistry of intestinal metaplasia in Barrett's esophagus. Mod Pathol, 1998; 1: 188-192
23. van Sandick JW, Van Lanschot JB, van Felius L, et al. Intestinal metaplasia of the esophagus or esophagogastric junction. Am J Clin Pathol, 2002; 117:117-125
24. Ormsby AH, Goldblum JG; Rice TW, et al. Cytoketatin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol, 1999; 30:288-294
25. Ormsby AH, Vaezi MF, Richter JE, et al. Cvtokeratin immunoreacitivity patterns??in the diagnosis of short-segment Barrett's esophagus. Gastroenterology, 2000; 119:683-690
26. Couvelard A, Cauvin J-M, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 2001; 49: 761-766
27. Gulmann C, Shaqaqi OA, Grace A, et al. Cytokeratin 7/20 and MUC1, 2, 5AC, and 6 expression patterns in Barrett's esophagus and intestinal metaplasia of the stomach: intestinal metaplasia of the cardia is related to Barrett's esophagus. Appl Immunohistochem Mol Morphol, 2004; 12: 142-147
28. Ei-Zimaity HM, Graham DY. Cytokeratin subsets for distinguishing Barrett's esophagus from intestinal metaplasia in the cardia using endoscopic biopsy specimens. Am J Gastroenterol, 2001; 96: 1378-1382
29. Mohammed IA, Streutker CJ, Riddell RH. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett's esophagus and gastric cardiac intestinal metaplasia. Mod Pathol, 2002; 15: 611-616
30. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology, 1999; 35: 517-524
31. Guillem P, Billeret V, Buisine MP, et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer, 2000, 88: 856-861
32. Kim BW, Kim KM, Lee BI, et al. Expression of trefoil peptides in the subtypes of intestinal metaplasia. Peptides, 2004; 25: 779-783
33. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett's esophagus. Am J Gastroenterol, 2002; 97: 2514-2523
34. Glickman JN, Wang H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal junction: an immunohistochemical study of cytokeratins 7 and 20, Das-1 and 45 ML. Am J??Surg Pathol, 2001; 25: 87-94
35. Polkowski W, van Lanschot JJ, Kate FJ, et al. The value of p53 and Ki67 as markers for tumor progression in the Barrett's dysplasia-carcinoma sequence. Surg Oncol, 1995; 4: 163-171
36. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 2002; 122: 1800-1807
37. Tselepis C, Perry I, Dawson C, et al. Tumor necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene, 2002; 21: 6071-6081
38. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc, 2001; 76: 438-446
39. Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett's oesophagus. Gut, 2005; 54: i38-i42
40. Doak SH, Jenkins GJS, Parry EM, et al. Chromosome hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut, 2003; 52: 623-628
41. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut, 2005; 54;6-12
42. Pera M, Cameron AJ, Trastek VF et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology, 1993, 104: 510-513
43. Cameton AJ, Lomboy CT, Pera M, et al. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology, 1995; 109: 1541-1546
44. Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis, 2003; 14: 128-135
45. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology, 1996; 110: 614-621
46. Ortiz Hidalgo C, De La Vega G, Aguirre Garcia J. The histopathology and biologic prognostic factors of Barrett's esophagus: a review. J Clin Gastroenterol,??1998; 26:324-333
47. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA, 2001; 285: 2331-2338
48. Lagergren J, Nandurkar S, Talley N, et al. Gastroesophageal reflux with symptom: a dangerous factor of esophageal adenocarcinoma. N Engl J Med, 1999; 340: 825-831
49. Sharma P. Recent advances in Barrett's esophagus: short segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis, 1999; 10: 93-102
50. Stephen S. Sternberg. Histology for pathologists. New York: Lippincott-Raven Publishers. Second Edition, 1997,461-493
51. Spechler SJ. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology, 2004; 126: 567-575
52. McClave SA, Boyce HW Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic criterion. Gastrointest Endosc, 1987; 33: 413-416
53. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol, 1998; 93: 1033-1036
54. Chandrasoma P. Pathophysiology of Barrett's esophagus. Semin Thorac Cardiovasc Surg, 1997; 9: 270-278
55. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology, 1998; 114: 633-639
56. Spechler SJ. Are we underestimating acid reflux? Gut, 2004; 53: 162-163
57. Watanabe T, Tada M, Nagai H, et al. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology, 1998; 115: 642-648
58. Oberg S, Peters JH, DeMeester TR, et al. Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Am Surg, 1997; 226: 522-53259. Manuel Pera. Trends in incidence and prevalence of Specialized Intestinal Metaplasia, Barrett's Esophagus, and Adenocarcinoma of the gastroesophageal Junction. World J Surg, 2003; 10:999-1008
60．常英，龚均，刘斌等。内镜检查中胃贲门部肠上皮化生的研究。西安交通大学学报(医学版)，2004；25：350-352
61．王立东，冯常炜，邹建湘等。食管癌高发区楼村居民贲门与胃窦上皮病变的比较。河南医科大学学报，1997；32：53-54
62．王俊宽，王立东，焦新英等。贲门癌癌旁肠上皮化生检测。郑州大学学报医学版，2006；41：14-16
63. Dresner SM, Griffin SM, Wayman J, et al. Human model of duodenogastro-oesophageal reflux in the development of Barrett's metaplasia. Br J Surg, 2003; 90:1120-1128
64. Couvelard A, Cauvin JM, Goldfain D, et al. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 2001; 49:761-766
65. Gao SG, Wang LD, Fan ZM, et al. Histochemical studies on intestinal metaplasia adjacent to gastric cardia adenocarcinoma in subjects at high-incidence area in Henan, north China. World J Gastroenterol, 2005; 11: 4634-4637
66. Sarbia M, Donner A, Franke C, et al. Distinction between intestinal metaplasia in the cardia and in Barrett's esophagus: the role of histology and immunohistochemistry. Hum Pathol, 2004; 35:371-376
67. Kurtkaya-Yapicier O, Gencosmanoglu R, Avsar E, Bakirci N, Tozun N, Sav A. The utility of cytokeratins 7 and 20 (CK7/20) immunohistochemistry in the distinction of short-segment Barrett esophagus from gastric intestinal metaplasia: Is it reliable? BMC Clin Pathol, 2003; 3:5-12
68．冯笑山，高社干，马保根等。贲门癌癌旁和无症状人群贲门黏膜活检肠上皮化生组织中p53和PCNA的表达。郑州大学学报医学版，2006；41：30-32
69. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric eardia. Gut, 2000; 46:9-1370. Hirota WK, Loughney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology, 1999; 116: 277-285
71. Sampliner RE, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol, 2002; 97: 1888-1895
72. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology, 2003; 125: 586-590
73. Dixon MF. Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia. Gut, 2001; 49:2-4
74. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut, 2003; 52: 1-4
75. Sakaki N, Kozawa H, Egawa N, et al. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther, 2002; 16: 198-203
76. Prabhu SR, Amrapurkar AD, Amrapurkar DN. Role of Helicobater pylori in gastric carcinoma. Natl Med India, 1995; 8: 58-60
77. Matsukura N, Onda M, Tokunaga A, et al. Mucosal IgA antibody against Helicobacter pylori in chronic gastritis and intestinal metaplasia detected by the Tes-Tape method in resection specimens after gastrectomy for gastric cancer. Cancer, 1995; 75: 1472-1477
78. Kneller RW, You Weicheng, Chang Yunsheng, et al. Cigarette smoking and other risk factors for the progression of precancerous stomach lesions. J Natl Cancer Inst. 1992; 84: 1261-1266
79. Stemmermann GN, Nomura MY, Chyou PH, et al. Impact of diet and smoking on risk of developing intestinal metaplasia of the stomach. Dig Dis and Sci, 1990; 35: 433-438
80. Yanai H, Takada K, Shimizu N, et al. Epstein-Barrvirus infection in non-carcinoma gastric epithelium. J Pathol, 1997; 183: 293-29881．杨光霖。胃粘膜肠化生类型及其在胃粘膜活检中的意义。临床与实验病理学杂志，1991，7：327-330
82. Eidt S, Stolte M. Prevalence of intestinal metaplasia in Helicobacter pylori gastritis. Scand J Gastroenterol, 1994; 29:607-610
83．徐光炜，游伟程，昌云生等。胃癌预防的研究。中国肿瘤临床，1998；25： 782-785
84．谢玉泉，李吉友，胡綝等。胃癌高发区肠上皮化生与异型增生的关系。北京医科大学报，1998；30：78-80
85. Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. Word J Gastroenterol, 2005; 11: 7131-7135
86. You WC, Zhang L, Gail MH, et al. Precancerous lesions in two counties of China with contrasting gastric cancer risk. Int J Epidemiol, 1998; 27:945-948
87. Rubio CA, Jonasson J, Nesi G. et al. Extensive intestinal metaplasia in gastric carcinoma and in other lesions requiring surgery: a study of 3,421 gastrectomy specimens from dwellers of the Atlantic and Pacific basins. J Clin Pathol, 2005; 58:1271-1277
88. Spechler SJ. The role of gastric carditis in metaplasia and neoplasia at the Gastroesophageal junction. Gastroenterology, 1999; 117:218-228
89. Fraser AG; Peng SL, Jass JR. Intestinal metaplasia subtypes and Helicobacter pylori infection: a comparison of ethnic groups in New Zealand. J Gastroenterol Hepatol, 1998; 13:560-565
90. El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY. Gastric intestinal metaplasia: subtypes and natural history. J Clin Pathol, 2001; 54:679-683
91．沈金库，林静，张林西等。胃黏膜上皮肠化类型与胃癌相关性研究。胃肠病学与肝病学杂志，1998；7：384-386
92. Shiao YH, Rugge M, Correa P, et al. p53 alteration in gastric precancerous lesions. Am J Pathol, 1994; 144:511-517
93. Sung JJY, Leung WK, Go MYY, et al. Cyclooxygenase-2 expression in??Helicobacter pylori -associated pre-malignant and malignant gastric lesions. Am J Pathol, 2000; 157: 729-735
94. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell, 1995; 83: 493-501
95. Filipe MI, Osborn M, Linehan J, et al. Expression of transforming growth factorα, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer, 1995; 71: 30-36
96. Yu J, Leung WK, Ng EK, et al. Effect of H. pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther, 2001; 15: 1505-1512
97. Yamamoto H, Bai YQ, Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun, 2003; 300: 813-818
98. Bai YQ, Yamamoto H, Akiyama Y, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett, 2002; 176: 47-55
99. Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology, 2002; 123: 1565-1577
100. Mutoh H, Sakurai S, Satoh K, et al. CDX1 induced intestinal metaplasia in the transgenic mouse stomach: Comparative study with CDX2 transgenic mice. Gut, 2004; 53:1416-1423
101. Leung WK, Kim JJ, Kim JG, et al. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol, 2000; 156: 537-543
102. Leung SY, Yuen ST, Chung LP, et al. hMLHl promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequencymicrosatellite instability. Cancer Res, 1999; 59: 159-164
103. To KF, Leung WK, Lee TL, et al. Promoter hypermethylation of tumor-related ??genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer, 2002; 102:623-628
104. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res, 2001; 61:2847-2851
105. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med, 2005; 25:197-222
106. Lauwers GY. Defining the pathologic diagnosis of metaplasia, atrophy, dysplasia, and gastric adenocarcinoma. J Clin Gastroenterol, 2003; 36:S37-S43
107. You WC, Li JY, Blot WJ, et al. Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer, 1999; 83:615-619
108. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 2001; 345:784-789
109. Leung WK, Sung JJY. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmachol Ther, 2002; 16:1209-1216
110．谢辉，王莉，顾霞。不同粘液物质与胃癌关系的研究。新疆医科大学学报，2005； 28：443-445
111. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer, 1994; 57:324-329
1l2. Genta RM, Rugge M. Review article: pre-neoplastic states of the gastric mucosa——a practical approach for the perplexed clinician. Aliment Pharmacol Ther, 2001; 15:43-50
113. Cassaro M, Rugge M, Gutierrez O, et al. Topographic pattems of intestinal metaplasia and gastric cancer. Am J Gastroenterol, 2000; 95:1431-1438
114. Hansson LE, Nyren O, Hesting AW. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med, 1996, 335:242-249
115. Hattori T. Development of gastric carcinomas of the stomach. Cancer, 1986; 57: 1528-1534
116. Meining A, Morgner A, Miehlke S, et al. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Beat Practice & Reasearch. 2001: 15:983-998117.Ectors N, Dixon MF. The prognostic value sulohomucin positive intestinal metaplasia in development of gastric cancer. Histopathology, 1986; 10: 1271-1277